The UPR-CTU has been on the forefront of the HIV/AIDS clinical research in the island of Puerto Rico and has the longest experience with participation on observational studies, perinatal interventions, clinical and behavior intervention and more recently prevention trials and studies. The Integrated University of Puerto Rico Clinical Trials Unit (UPR-CTU/60446) is a coalition/merger of the three previous independent Clinical Trials Sites associated to the ACTG, HVTN and PACTG research Networks. The UPR-CTU, has 3 Clinical Research Sites which have worked with the Leadership Networks established to further advance the high priority areas relating to: adult HIV therapeutic strategies, including HIV cure, noninfectious comorbidities, and the infectious comorbidities of hepatitis and tuberculosis; strategies to address HIV and HIV-associated infections in pediatric and maternal populations and vaccines to prevent HIV infections. We have also carried out studies sponsored by other networks (MTN, ATN, and HPTN) that target integrated HIV prevention strategies and microbicide strategies to prevent HIV infections. With this proposal we will further integrate the functions of the UPR-CTU by establishing nine (9) divisions that will constitute the centralized operations arm of the UPR-CTU: Administration and Financial Affairs. Clinical Staff and Investigators (funded with PIF); Pharmacy, Coordination and Training, Central Laboratory, Data Coordination, Regulatory Affairs, Quality Management/Evaluations and Community Engagement in order to improve the efficacy and utilization of resources. We will conduct research in following six research areas: 1) Adult HIV therapeutic strategies, including HIV cure, noninfectious comorbidities, and the infectious comorbidities of hepatitis and tuberculosis; 2) Strategies to address HIV and HIV-associated infections in pediatric and maternal populations; 3) Integrated HIV prevention strategies; 4) Microbicide strategies to prevent HIV infections; and 5) Vaccines to prevent HIV infections. Among the significant aspects of this proposal are the topics of interest and research, the availability of diverse groups of interest such as: people living with HIV, populations with diverse degrees of risk for HIV, populations with specific characteristics or risk behaviors (MSM, commercial sex workers, LGBTT, IDUs, adolescents, women and children) and the experience and diversity of disciplines integrated into this CTU.
The Integrated University of Puerto Rico Clinical Trials Unit will provide access to clinical, behavior and prevention trials to a large number of participants of Hispanic ethnicity located in Puerto Rico contributing to the research agenda in areas relating to: adult HIV therapeutic strategies, comorbidities; strategies to address HIV and HIV-associated infections in pediatric and maternal populations and vaccines to prevent HIV infections.
|Nixon, Daniel E; Bosch, Ronald J; Chan, Ellen S et al. (2017) Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A52 J Clin Lipidol 11:61-69|
|Gulick, Roy M; Wilkin, Timothy J; Chen, Ying Q et al. (2017) Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial. Ann Intern Med 167:384-393|
|Gulick, Roy M; Wilkin, Timothy J; Chen, Ying Q et al. (2017) Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305). J Infect Dis 215:238-246|
|Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111|
|Riddler, Sharon A; Aga, Evgenia; Bosch, Ronald J et al. (2016) Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. J Infect Dis 213:556-60|
|Landovitz, Raphael J; Tran, Thuy Tien T; Cohn, Susan E et al. (2016) HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States. AIDS Behav 20:2983-2995|
|Chan, Ellen S; Landay, Alan L; Brown, Todd T et al. (2016) Differential CD4+ cell count increase and CD4+?: ?CD8+ ratio normalization with maraviroc compared with tenofovir. AIDS 30:2091-7|
|Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68|
|Tashima, Karen T; Smeaton, Laura M; Fichtenbaum, Carl J et al. (2015) HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial. Ann Intern Med 163:908-17|
|Tenorio, Allan R; Chan, Ellen S; Bosch, Ronald J et al. (2015) Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286. J Infect Dis 211:780-90|
Showing the most recent 10 out of 52 publications